Different types of Drug-induced Liver Injury (DILI) Drug-induced liver injury (DILI) is a longstanding and significant problem for clinicians,
The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place.
What is the FDA Modernization Act 2.0, and what does it mean? The U.S. Food and Drug Administration (FDA) are the federal agency tasked with
Pharmacokinetics in mice… or a microfluidic device!
Xenograft mouse models have long been the gold standard method for preclinically assessing the relationship between PK/PD and efficacy. However,
MPS World Summit round-up
If you could not attend the inaugural Microphysiological System (MPS) World Summit in New Orleans earlier this month, but it is on your radar for
The lung in crisis: fighting back against pathogens, infections and inflammation with predictive in vitro lung models that accelerate drug discovery
The human lung is in crisis Our lungs represent the only internal organ that is directly subject to the environment and therefore face a relentless
Debunking the 9 myths of Organ-on-a-chip technology
Organ-on-a-chip (OOC) technology offers you a transformative approach to better science. By bridging the gaps between traditional cell culture, animal
De-risking drug-induced liver injury through the predictive power of organ-on-a-chip
The liver is responsible for metabolizing most medications, and as such represents one of the primary tissues affected by adverse drug reactions.
De-risking pre-clinical drug-induced liver injury with organ-on-a-chip
Drug-induced liver injury (DILI) is a potential complication of nearly all classes of medication. It's not at all uncommon for DILI to pass undetected
Changing times, why pharmacokinetics matter in drug discovery
Drug discovery should be simple. Deliver the right molecule, antibody, new modality, or cell to the right target within the right organ at the right